Callan JMB signs strategic teaming agreement with Biostax Corp

Callan JMB (CJMB) announced it has signed a strategic teaming agreement with Biostax Corp d/b/a Attune Biotech, a clinical-stage biopharmaceutical company with a diversified therapeutic pipeline. Callan JMB will serve as independent third-party overseer of Attune ‘s manufacturing, quality assurance and control, and deployment operations. Under the agreement, Callan JMB will provide federal oversight services, including manufacturing quality assurance and independent batch record review, Biomedical Advanced Research and Development Authority contract compliance, Food and Drug Administration audit readiness and mock inspections, milestone tracking, and federal reporting, supply chain governance and supplier qualification, and Strategic National Stockpile deployment coordination.